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Cathepsin BInﬂammasomes play a critical role in the development of vascular diseases. However, themolecularmechanisms
activating the inﬂammasome in endothelial cells and the relevance of this inﬂammasome activation is far from
clear. Here, we investigated themechanisms by which an Nlrp3 inﬂammasome is activated to result in endothe-
lial dysfunction during coronary arteritis by Lactobacillus casei (L. casei) cell wall fragments (LCWE) in a mouse
model for Kawasaki disease. Endothelial dysfunction associated with increased vascular cell adhesion protein 1
(VCAM-1) expression and endothelial–leukocyte adhesion was observed during coronary arteritis in mice treat-
ed with LCWE. Accompanied with these changes, the inﬂammasome activation was also shown in coronary ar-
terial endothelium, which was characterized by a marked increase in caspase-1 activity and IL-1β production.
In cultured endothelial cells, LCWE induced Nlrp3 inﬂammasome formation, caspase-1 activation and IL-1β pro-
duction, which were blocked by Nlrp3 gene silencing or lysosome membrane stabilizing agents such as colchi-
cine, dexamethasone, and ceramide. However, a potassium channel blocker glibenclamide or an oxygen free
radical scavenger N-acetyl-L-cysteine had no effects on LCWE-induced inﬂammasome activation. LCWE also in-
creased endothelial cell lysosomal membrane permeability and triggered lysosomal cathepsin B release into cy-
tosol. Silencing cathepsin B blocked LCWE-induced Nlrp3 inﬂammasome formation and activation in endothelial
cells. In vivo, treatment of mice with cathepsin B inhibitor also abolished LCWE-induced inﬂammasome activa-
tion in coronary arterial endothelium. It is concluded that LCWE enhanced lysosomal membrane perme-
abilization and consequent release of lysosomal cathepsin B, resulting in activation of the endothelial Nlrp3
inﬂammasome, which may contribute to the development of coronary arteritis.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Recently, a new concept is emerging that activation of the
inﬂammasomes, in particular, the Nlrp3 (nucleotide-binding domain
and leucine-rich repeat pyrin domain containing 3) inﬂammasome,
plays a critical role in the development of vascular diseases [1–3].
It has been known that the Nlrp3 inﬂammasome usually consists of
threemain components including Nlrp3 that functions as a pattern rec-
ognition receptor, the adaptor protein, ASC (apoptotic speck-containing
protein with a CARD) and inactive pro-caspase-1 protein [4]. This
inﬂammasome serves as intracellular machinery responsible for
the production of important pro-inﬂammatory cytokines such as
interleukin-1β (IL-1β) and interleukin-18 (IL-18) [5,6], thereby produc-
ing inﬂammatory response. Recently, Nlrp3 inﬂammasome activation
has also been reported to produce the regulatory or pathogenic actions
in cells or tissues beyond the classical inﬂammatory response. These ac-
tions beyond inﬂammation include pyroptosis, a speciﬁc form of cell1 804 828 4794.
1 804 828 4794.
cu.edu (P.-L. Li).death that combines the characteristics of apoptotic and necrotic
death pathways [7–9], changes in cell membrane permeability by enzy-
matic reaction [10], interference with cytoskeleton arrangement [11],
and direct inhibition of functional protein synthesis and metabolism in
cells with activated inﬂammasomes. There is increasing evidence that
these non-inﬂammatory actions of inﬂammasome activation may also
be important in the regulation of cell function and in the mediation of
different diseases [12]. However, the molecular mechanisms activating
the Nlrp3 inﬂammasome in various cells and the relevance of this
inﬂammasome activation is far from clear.
TheKawasaki diseasemodel is characteristic of typical inﬂammatory
cardiovascular diseases given its major pathological changes related to
the inﬂammation in the walls of small- and medium-sized arteries,
coronary arteries in particular [13]. L. casei cell wall fragment (LCWE)-
induced coronary arteritis is a well-established model that histopatho-
logically mimics the coronary arteritis of Kawasaki disease [14,15]. To
date, the etiologic agent for Kawasaki disease is yet to be discovered,
however, in the LCWE model, typical pathological changes in coronary
arteries are similar to those of Kawasaki disease patients including in-
creased production of inﬂammatory cytokines in coronary arterial
wall, inﬁltration of inﬂammatory cells, and aneurysm formation [16,
397Y. Chen et al. / Biochimica et Biophysica Acta 1853 (2015) 396–40817]. Further, it has been shown that the LCWE model of coronary
arteritis is useful in duplicating or predicting human treatment re-
sponses because anti-TNF-α mAbs and intravenous gamma globulinwere found to be effective in preventing coronary lesions in this
model [14]. Therefore, it is of interest to investigate themolecularmech-
anisms for LCWE-induced cellular activation in the cardiovascular
Fig. 2. Activation of endothelial inﬂammasomes in coronary arteries of mice treatedwith LCWE. Mice were intraperitoneally treated with saline control (Ctrl) or LCWE (500 μg, 2 weeks).
(A) Frozen sections ofmouse hearts were stainedwith FLICA, a greenﬂuorescent probe speciﬁc for active caspase-1, and Alexa555-conjugated antibodies against an endothelial cellmark-
er vWF in coronary arteries. The merged images displayed yellow dots or patches indicating the colocalization of FLICA (green) with vWF (red). Summarized data showing the
colocalization coefﬁcient of FLICAwith vWF (n=5). (B) IHC staining showing the expression of IL-1β in the endothelium of coronary arteries. Summarized data showing area percentage
of the endothelium positive for IL-1β in coronary arteries. High-power magniﬁcation of AOI is indicated with an arrow. Scale bar = 50 μm. n = 6 mice per group. *P b 0.05 vs. control.
398 Y. Chen et al. / Biochimica et Biophysica Acta 1853 (2015) 396–408system. Here, we aim to investigate the molecular activation of
inﬂammasomes in endothelial cells by LCWE and address the implication
of endothelial inﬂammasomes in the development of coronary arteritis.
In the present study, we ﬁrst determined whether the Nlrp3
inﬂammasome is activated in response to LCWE in endothelial cells
in vivo and in vitro. We then explored molecular mechanisms mediating
Nlrp3 inﬂammasome activation by LCWE. Different possible pathways to
activate this inﬂammasomewere tested including lysosomal dysfunction
and consequent release of cathepsin B, the effects of reactive oxygen spe-
cies (ROS), and potassium channel-mediated membrane potassium
movements. It is suggested that Nlrp3 inﬂammasome activation in coro-
nary endothelial cells during LCWE stimulationmay trigger and promote
the endothelial dysfunction during coronary arteritis and that lysosomal
stabilization is critical for the integrity of endothelial structure and func-
tion due to its action to inhibit inﬂammasome activation.2. Materials and methods
2.1. Preparation of LCWE
The model of Kawasaki disease was prepared as previously de-
scribed [14]. Brieﬂy, L. casei bacteria (American Type Culture Collection,
Manassas, VA) (ATCC 11578) were cultured in Lactobacillus MRS broth
(BD Systems, USA) at 37 °C (on a shaker platform) and then harvested
by centrifugation (10, 000 ×g, 40 min) during the log phase of growth.Fig. 1. Increased VCAM-1 expression and leukocyte adhesion in coronary arterial endothelium
(Ctrl) or LCWE (500 μg, 2 weeks). (A) IHC staining showing the expression of VCAM-1 in the e
thelium positive for VCAM-1 staining in coronary arteries. (B) IHC staining showing the expre
showing area percentage of the endothelium positive for the neutrophil marker in coronary ar
of coronary arteries. Summarized data showing area percentage of the endotheliumpositive for
F4/80 in the endothelium of coronary arteries. Summarized data showing area percentage of th
(AOI) are indicated with an arrow. Scale bar: 50 μm. N = 6 mice per group. *P b 0.05 vs. LCWEAfter 6 washes with PBS (pH 7.2), L. casei bacteria were lysed by over-
night incubation (at room temperature on a shaker platform) with 4%
SDS (Sigma-Aldrich, St. Louis, MO, USA) followed by 8 washes with
PBS. The samples were then sequentially incubated with 250 μg/ml
RNase, DNase I, and trypsin (Sigma-Aldrich, St. Louis, MO, USA) to re-
move any adherent material from the cell walls. Each incubation was
followed by 2washes in PBS and then 4washes only after an incubation
with trypsin. After centrifugation, the pellet was sonicated (3 g of
packed wet weight in 9 ml of PBS) in a dry ice/ethanol bath for 2 h at
a pulse setting of 5.0 (10-s pulse/5-s pause) (550 Sonic Dismembrator
with a one-half-inch tapped horn and tapered microtip; one-eighth-
inch diameter, tuned to vibrate at a ﬁxed frequency of 20 kHz; Fisher
Scientiﬁc, Nepean, Canada). Following a 1-h centrifugation, the resul-
tant supernatant containing the LCWE was harvested for treatment.
The concentration of the preparation was detected by phenol-sulfuric
acid colorimetric determination of the rhamnose content and expressed
in mg/ml ﬁnal concentration in PBS [16].2.2. Animal procedures
C57BL/6Jmice (4weeks of age, male)were bred from breeding pairs
from The Jackson Laboratory, Bar Harbor, ME, USA. All protocols were
approved by the Institutional Animal Care andUse Committee of Virgin-
ia Commonwealth University. All mice were injected LCWE (i.p. 500 μg
per mouse) to produce coronary arteritis as described in previousof mice treated with LCWE.Mice were intraperitoneally treated with either saline control
ndothelium of coronary arteries. Summarized data showing area percentage of the endo-
ssion of the neutrophil marker in the endothelium of coronary arteries. Summarized data
teries. (C) IHC staining showing the expression of T cell marker CD43 in the endothelium
CD43 in coronary arteries. (D) IHC staining showing the expression ofmacrophagemarker
e endothelium positive for F4/80 in coronary arteries. Enlarged images of area of interest
on WT.
Fig. 3. Formation of Nlrp3 inﬂammasome inMVECs upon LCWE stimulation. (A, B)MVECswere stained with Alexa488-conjugated anti-Nlrp3 and Alexa555-conjugated anti-ASC or anti-
caspase1 antibodies. Representative images in panel A show the colocalization (yellow) of Nlrp3 (green) with ASC (red) or Nlrp3 (green)with caspase-1 (red) under stimulation of LCWE
(10 μg/ml) for 0–24 h. Summarized data in panel B show the colocalization coefﬁciency of Nlrp3 with ASC or Nlrp3 with caspase-1 (n= 5). *P b 0.05 vs. LCWE 0 h. (C) MVECswere stim-
ulatedwithout (Ctrl) or with LCWE (10 μg/ml) for different time points (2, 4, 8, 16, and 24 h) and then lysed. Cell lysates were used for size-exclusion chromatography (SEC) followed by
Western blot analysis of eluted fractions using antibodies against pro-caspase-1. Summarizeddata show the percentage of pro-caspase-1 expression in thehighmolecularweight fractions
(#12–14) compared to total expression of pro-caspase-1 (#1–14) (n = 3). *P b 0.05 vs. Ctrl.
399Y. Chen et al. / Biochimica et Biophysica Acta 1853 (2015) 396–408studies [14]. After 2 weeks, mice were sacriﬁced and heart tissues were
harvested for immunohistochemistry and immunoﬂuorescence
examinations.
2.3. Cell culture
The mouse vascular endothelial cell (MVEC) line was purchased
from ATCC (CRL-2586) and cultured as previously described [18]. Thecell line was originally isolated from mouse hemangioendothelioma.
MVECs were cultured in Dulbecco's modiﬁed Eagle's medium (DMEM)
(Gibco, USA), containing 10% of fetal bovine serum (Gibco, USA) and
1% penicillin–streptomycin (Gibco, USA). The cells were cultured in a
humidiﬁed incubator with a mixture of 5% CO2 and 95% air at 37 °C.
Cells were passaged by trypsinization (Trypsin/EDTA; Sigma, USA),
followed by dilution in DMEM medium containing 10% fetal bovine
serum.
Fig. 4. LCWE increased Nlrp3 inﬂammasome activity in MVECs. (A) Representative immunoblotting documents and summarized data showing the effects of LCWE (10 μg/ml for 0–24 h)
on the expression of pro-caspase-1, cleaved caspase-1 andβ-actin inMVECs (n=4). *P b 0.05 vs. LCWE0h. (B) Effects of LCWE (10 μg/ml for 0–8 h) on IL-1β production inMVECs (n=6).
*P b 0.05 vs. LCWE0h. (C) RepresentativeWestern blot documents and summarized data showing the effect of LCWE (10 μg/ml, 8 h) on the expression of pro-caspase-1, cleaved caspase-1
and β-actin expression in MVECs transfected with scrambled shRNA (Scr) or Nlrp3 shRNA plasmids (n = 4). *P b 0.05 vs. scrambled control; #P b 0.05 vs. scramble + LCWE.
400 Y. Chen et al. / Biochimica et Biophysica Acta 1853 (2015) 396–4082.4. Immunohistochemistry
Hearts were embedded with parafﬁn, and 4 μm slices were cut from
the embedded blocks. The tissue sectionswere stained with rabbit anti-
VCAM-1 (1:50, Abcam, Cambridge, MA), anti-CD43 (1:50, Santa Cruz
Biotech., CA), anti-F4/80 (1:50; AbD Serotec, Raleigh, NC), anti-
Neutrophil marker (1:50, Santa Cruz Biotech., CA), and anti-IL1β
(1:50, R&D systems, MN) overnight at 4 °C after a 20 min wash with
4% H2O2 and 30 min blocking with 10% serum. Slides were incubated
with primary antibodies diluted in phosphate-buffered saline (PBS)
with 4% serum. After incubation with each of these primary antibodies
overnight, the sectionswerewashed in PBS, incubatedwith biotinylated
IgG (1:200) for 1 h, and then incubated with streptavidin-horseradish
peroxidase for 30 min at room temperature. 50 μl of DAB were added
to each section and stained for 1 min. After washing, the slides were
counterstained with hematoxylin for 5 min. The slides were then
mounted and observed under a microscope where photos were taken
of the tissues. The area percentage of the endothelium positive for indi-
cated staining in coronary arteries were analyzed by Image Pro Plus
software (Media Cybernetics, Inc., Bethesda, MD).2.5. Immunoﬂuorescence microscopy
To conﬁrm inﬂammasome activation in the endothelium of mouse
coronary arteries, a FAM FLICA™ Caspase 1 Assay Kit (ImmunoChemis-
try Technologies, LLC, Bloomington, MN, USA)was used to detect active
caspase-1 by FLICA probes. Frozen slideswere ﬁxed in acetone for 1min
then incubated overnight at 4 °Cwith sheep anti-vWF antibody (1:200;
Abcam, Cambridge,MA, USA) or anti-F4/80 (1:50; AbD Serotec, Raleigh,
NC). Then, FLICA (1:10) and the ﬂuorescence-conjugated secondary
antibody were co-incubated for 1.5 h at room temperature. Then, the
slideswerewashed,mounted, andwere visualized through sequentially
scanning on an Olympus laser scanning confocal microscope (Fluoview
FV1000, Olympus, Japan). For cell staining, MVECs grown on glass
coverslips were treated as indicated and then ﬁxed in 4% PFA for
15 min. Cells were washed in phosphate-buffer saline (PBS) and incu-
bated for 2 h at 4 °C with the indicated combination of goat anti-Nlrp3
(1:200, Abcam), rabbit anti-ASC (1:50, Santa Cruz Biotech.), or mouse
anti-caspase-1 (1:100, Santa Cruz Biotech.) antibodies. Then cells were
stained for another hour with ﬂuorescence-conjugated secondary
antibodies (1:500, Invitrogen) as indicated [19]. Then, slides were
Fig. 5. Effects of potassium channel blockade or ROS scavenging on LCWE-induced activa-
tion of Nlrp3 inﬂammasomes in MVECs. MVECs were stimulated with or without LCWE
(10 μg/ml, 8 h) in the presence of PBS (Vehl: vehicle), potassium channel blocker
glibenclamide (GLY, 10 μM, Sigma) or ROS scavenger N-acetyl-L-cysteine (NAC, 10 μM,
Sigma). (A) Representative Western blot documents and summarized data showing the
effects of glibenclamide or N-acetyl-L-cysteine on the expression of pro-caspase-1, cleaved
caspase-1 and β-actin (n = 3). (B) IL-1β production measurement in MVECs by ELISA
(n = 6). *P b 0.05, LCWE vs. control; #P b 0.05 vs. vehicle + LCWE.
401Y. Chen et al. / Biochimica et Biophysica Acta 1853 (2015) 396–408similarly processed and visualized as above. Co-localization in coronary
arteries or cells was analyzed by Image Pro Plus software, and the co-
localization coefﬁcient was represented by Pearson's correlation
coefﬁcient.
2.6. Preparation of cytosolic fractions
Cells were washed twice with PBS and then homogenized in ice-
cold HEPES buffer containing 20 mM HEPES, 255 mM sucrose, 1 mM
EDTA, and 0.1 mM phenylmethylsulfony1 ﬂuoride (pH 7.4). The
supernatants (termed homogenates) containing membrane and cy-
tosolic fractions were obtained by centrifugation of samples at
1000 ×g for 10 min at 4 °C. A portion of homogenates was frozen in
liquid N2 and stored at −80 °C until use. Cytosolic fractions were
prepared by a sequential centrifugation of the homogenates at
10,000 ×g for 20 min and 100,000 ×g for 90 min, as described previ-
ously [20].
2.7. Immunoblotting
Proteins from the MVECs were extracted using sucrose buffer
(20mMHEPES, 1mMEDTA, 255mM sucrose, and a cocktail of protease
inhibitors (Roche), pH 7.4). 20 μg protein samples were then denatured
with 5× reducing Laemmli SDS-sample buffer and heated at 95 °C for5 min. Samples were run on SDS-PAGE gel, transferred onto a PVDF
membrane and blocked. The membranes were then probed with a
primary antibody of either anti-caspase-1 (1:500, Santa Cruz Biotech)
or anti-cathepsin B (1:500, Abcam) overnight at 4 °C followed by incu-
bation with horseradish peroxidase-labeled IgG (1:5000, Santa Cruz
Biotech.). The immunoreactive bandswere enhanced by chemilumines-
cencemethods and imaged on Kodak Omat ﬁlm. Densitometric analysis
of the images obtained fromX-rayﬁlmswas performed using the Image
J software (NIH).
2.8. Size-exclusion chromatography (SEC)
Proteins from MVECs were extracted from the homogenized cells
with the following protein extraction buffer: 10 mM KCl, 20 mM 4-
(2-hydroxyethyl)-1-piperazineethanesulfonic acid-KOH (pH 7.5),
1 mM EGTA, 1.5 mM EDTA and a protease inhibitor cocktail
(Roche). Samples were ultra-centrifuged at 18,000 ×g for 10 min at
4 °C, the protein concentration of the supernatant was measured,
and 1 mg of protein was run on a Superose 6 10/300 GL Column,
with the following buffer: 50 mmol/l Tris (pH 7.4), 150 mmol/l
NaCl, 1% octylglucoside, and 1× protease inhibitor cocktail, connect-
ed to an ÄKTAprime plus chromatography system (GE Healthscience,
Uppsala, Sweden). Fractions (600 μl) were collected starting at the
void time and tested by Western blot. A 5 × loading buffer was
added directly to the fractions, heated at 95 °C for 5 min, run on
SDS-polyacrylamide gel electrophoresis gels, and transferred to a
PVDF membrane. After blocking, the membrane was probed with
anti-caspase-1 (1:500) overnight at 4 °C, followed by incubation
with horseradish peroxidase-labeled IgG (1:5000). The bands were
detected, visualized and analyzed as described for immunoblotting.
2.9. Nucleofection
Transfection of shRNA plasmids was performed using a 4D
Nucleofector X-Unit (Lonza) according to the manufacturer's instruc-
tions. The GFP-Nlrp3 plasmid was obtained from Origene. Brieﬂy,
MVECs were trypsinized and centrifuged at 80 ×g for 10 min. The cell
pellet was resuspended in 100 μl SF Nucleofector™ solution (Lonza)
for nucleofection (with the program code DS198). This program was
chosen based on the fact that nucleofection efﬁciency was over 80% as
analyzed by ﬂow cytometry using control GFP plasmids. For each
nucleofection sample, 2 μg plasmid DNA was added in 100 μl P1
nucleofection solution. After nucleofection, cells were cultured in
DMEMmedium for 24 h.
2.10. Analysis of lysosome membrane permeability
MVECs were cultured in eight-well chamber slides or 24-well cul-
ture plates and treated without or with LCWE for the indicated time,
or treated with glycyl-phenylalanine-2-naphthylamide, a lysosome-
disrupting agent. Cells were then incubated with 1 μM acridine orange
for 20min at 37 °C, rinsedwith PBS. Cells in chamber slides were imme-
diately analyzed and photographed using a ﬂuorescence microscope
(Fluoview FV1000, Olympus, Japan). Cells in culture plates were ana-
lyzed for red-to-green ﬂuorescence ratio of acridine orange staining
by ﬂow cytometry analysis using a ﬂow cytometer (GUAVA, Hayward,
CA, USA).
2.11. RNA interference of cathepsin B
Small interference RNAs (siRNAs) for cathepsin B gene and scram-
bled small RNAwere commercially available (Santa Cruz Biotechnology,
CA). Transfection of siRNAwas performed using the siLentFect Lipid Re-
agent (Bio-Rad, CA, USA) according to the manufacturer's instructions.
Fig. 6. LCWE-induced activation of Nlrp3 inﬂammasomes is associated with increased lysosome membrane permeability. MVECs were stimulated without (control: Ctrl) or with LCWE
(10 μg/ml, 8 h) in either the absence or presence of lysosomal function stabilization reagents (Vehl: vehicle only; Col: colchicine, 10 μM; Cer: C2-ceramide, 20 μM, Enzo Life Sciences; and
Dex: dexamethasone, 100 μM, Sigma). (A and B)MVECs were stained with Alexa488-conjugated anti-Nlrp3 and Alexa555-conjugated anti-ASC or anti-caspase1 antibodies. Representa-
tive images show the colocalization (yellow) of Nlrp3 (green) with ASC (red) or Nlrp3 (green) with caspase-1 (red). Summarized data in panels A and B show the colocalization
coefﬁciency of Nlrp3 with ASC or Nlrp3 with caspase-1 (n = 5). (C) Western blot analysis of cleaved caspase-1 and pro-caspase-1 in MVECs (n = 6). (D) IL-1β production in MVECs
by ELISA (n = 6). *P b 0.05 vs. vehicle control; #P b 0.05 vs. vehicle + LCWE.
402 Y. Chen et al. / Biochimica et Biophysica Acta 1853 (2015) 396–4082.12. IL-1β production
After treatment, the cell supernatant was collected and IL-1β pro-
duction was measured by a commercially available ELISA kit (R&D Sys-
tem, Minneapolis, MN) according to the protocol described by the
manufacturer.2.13. Statistics
Data are presented as means ± SE. Signiﬁcant differences between
and within multiple groups were examined using ANOVA for repeated
measures followed by Duncan's multiple-range test. A student's t test
was used to detect signiﬁcant differences between two groups. The sta-
tistical analysis was performed using SigmaStat 3.5 software (Systat
Software, San Jose, CA). P b 0.05 was considered statistically signiﬁcant.3. Results
3.1. Increased vascular inﬂammation in coronary arteries in mice treated
with LCWE
LCWE-induced coronary arteritis is a widely used mouse model for
Kawasaki disease [14,15]. VCAM-1 is a key molecule in mediating the
adhesion of leukocytes including neutrophils, monocytes and lympho-
cytes, to vascular endothelium [21]. Increased expression of VCAM-1
has been considered as a marker for endothelial cell activation during
vascular inﬂammation. As shown in Fig. 1A, immunohistochemistry
(IHC) studies demonstrated that treatment ofmicewith LCWEmarked-
ly increased the expression of VCAM-1 in the intima of coronary arter-
ies. Such increase in VCAM-1 was further accompanied with increased
adhesion of inﬂammatory cells including neutrophils (Fig. 1B), T lym-
phocytes (Fig. 1C), and macrophages (Fig. 1D). It should be noted that
Fig. 7. LCWE increased lysosome membrane permeability and cathepsin B release in
MVECs. (A) MVECs were incubated with either LCWE (10 μg/ml) for 0, 2, 4 and 8 h or
GPN (100 μM) for 4 h. Lysosomemembrane permeability was detected by acridine orange
staining and visualization by ﬂuorescence microscopy. (B) Summarized data show the
red-to-green ﬂuorescence ratio of acridine orange staining in MVECs by ﬂow cytometry
analysis (n = 3). *P b 0.05 vs. LCWE 0 h. (C) Western blot analysis of cathepsin B expres-
sion in cytosolic fractions of MVECs with or without LCWE (10 μg/ml, 8 h) (n = 5).
*P b 0.05 vs. control.
403Y. Chen et al. / Biochimica et Biophysica Acta 1853 (2015) 396–408in the present study, LCWE (500 μg per mouse) induced only a mild le-
sion compared to a more severe lesion reported in the literature. This
discrepancy may be due to the difference in the purity of LCWE prepa-
rations. In our pilot experiments, we also found that LCWE at a higher
dose (1000 μg permouse, 2weeks) signiﬁcantly increased themortality
of mice (4 mice died out of the 6 mice; survival rate is only 33.33%),
whereas no mice died when treated with 500 μg LCWE for 2 weeks. In
the present study, we aimed to investigate whether and how endothe-
lial inﬂammasome is activated during coronary arteritis. LCWE at this
lower dose to induce coronary arteritis but not severe lesion is appropri-
ate for this purpose.3.2. Activation of endothelial inﬂammasomes in coronary arteries in mice
treated with LCWE
Next, we examined whether endothelial activation and vascular in-
ﬂammation are associatedwith activation of endothelial inﬂammasomes
in coronary arteries of LCWE-treated mice. To this end, the activation of
caspase-1 in the coronary arteries was detected by confocal microscopyusing FLICA, a greenﬂuorescent probe that speciﬁcally binds to the active
form of caspase-1 protein. The endothelium was visualized by staining
the coronary arteries with vWF, an endothelial cell marker. We detected
a basal level of caspase1 activity (FLICA) in coronary endothelium (vWF)
and found that 2-week LCWE (500 μg/mouse) treatment signiﬁcantly
increased the expression of active caspase-1 (FLICA) in the endothelium
(vWF) as shown by increased co-localization coefﬁcient between FLICA
(green) and vWF (red) (Fig. 2A). Consistently, the IHC studies demon-
strated that the expression of IL-1β, an inﬂammasome product, was
markedly enhanced in the intima of coronary arteries from LCWE-
treated mice (Fig. 2B). As shown in Supplementary Fig. S1, an increased
caspase1 activity can be detected in coronary endothelium of mice as
early as 3 days after LCWE treatment. In contrast, increases in VCAM-1
expression occur at 7 days after LCWE treatment (Supplemnetary
Fig. S2). No changes in leukocyte adhesion were found even after
7 days of LCWE treatment (Supplementary Fig. S3). Together, these
data suggest that LCWE activates endothelial inﬂammasomes in coro-
nary arteries in vivo, which is an earlier event compared to the forma-
tion of coronary arteritis.
3.3. Formation and activation of Nlrp3 inﬂammasome complex in MVECs
upon LCWE stimulation
Nlrp3 inﬂammasome has been demonstrated as the principal
machinery to trigger the inﬂammatory responses in a variety ofmamma-
lian cells including ECs [22].We then determinedwhether LCWE induces
Nlrp3 inﬂammasome formation and activation in ECs by analyzing
the colocalization of Nlrp3 inﬂammasome components, the formation
of a high-molecular-weight protein complex consisting of Nlrp3
inﬂammasome oligomers, the cleavage of pro-caspase-1 to active
caspase-1, and the production of IL-1β. As shown in Fig. 3A–B, LCWE
time-dependently increased the co-localization between Nlrp3 (green)
and ASC (red) as shown by increased yellow staining and co-
localization coefﬁcient (maximal co-localization was observed after 8-
hour LCWE stimulation). A similar increase in colocalization was found
betweenNlrp3 and caspase-1. Bryan et al. have reported amarked redis-
tribution of ASC fromnuclei to cytosol under inﬂammasome activation in
macrophages [23], which is different from the ASC expression pattern in
MVECs as we only observed a partial redistribution of ASC during
inﬂammasome activation by LCWE and adipokine visfatin as described
previously [18]. It is possible that ECs express a speciﬁc isoform which
has a different action than the isoform in macrophages [24].
The formation of the functional Nlrp3 inﬂammasome requires the
oligomerization of inﬂammasome monomers to form a high-
molecular-weight protein complex, where pro-caspase-1 proteins are
cleaved to their active forms. To detect such formation of the high-
molecular-weight protein complex, we ﬁrst performed size exclusion
chromatography (SEC) to isolate proteins from MVECs into different
fractions according to their size under the reduced condition and then
detected the recruitment of pro-caspase-1 proteins in the high-
molecular-weight fractions by Western blot. As shown in Fig. 3C, we
found that under a resting control condition, pro-caspase-1 proteins
were only detected in low-molecular-weight fractions, whereas a
marked increase in pro-caspase-1 expression was observed in high-
molecular-weight fractions when MVECs were treated with LCWE.
Such a shift of pro-caspase-1 from low-molecular-weight fractions
into high-molecular-weight fractions indicates the formation of
inﬂammasome complexes.
Consistent with the ﬁndings for the formation of Nlrp3 inﬂamma-
some complex, we further demonstrated that LCWE increased Nlrp3
inﬂammasome activity in MVECs as shown by enhanced cleavage of
pro-caspase-1 proteins to their bio-active form (p20 subunit) (Fig. 4A)
and production of IL-1β production (Fig. 4B), which peaked at 8 h
after LCWE treatment. Such an increase in inﬂammasome activation
was completely abolished in cells transfected with Nlrp3 shRNA plas-
mids compared to those transfected with scramble shRNA plasmids
Fig. 8. Effects of cathepsin B gene silencing on LCWE-induced Nlrp3 inﬂammasome activation.MVECswere transfectedwith scramble (Scr) or cathepsin B siRNA (CatBsi) for 24 h and then
stimulated with or without LCWE (10 μg/ml, 8 h). (A) Confocal ﬂuorescent images and summarized co-localization coefﬁcient show the co-localization (yellow) between Nlrp3 (green)
and caspase-1 (red) (n= 4). (B)Western blot analysis of cleaved caspase-1 and pro-caspase-1 (n= 4). (C) IL-1β production (n=6). (D)Western blot analysis of cathepsin B expression
in cell lysates of MVECs transfected with scramble or cathepsin B siRNA (n = 4). *P b 0.05 vs. scramble control; #P b 0.05 vs. scramble + LCWE.
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inﬂammasome formation and activation in human coronary arterial
ECs as shown by an increased co-localization between Nlrp3 and
caspase-1 or ASC and enhanced cleavage of pro-caspase-1 to active
caspase-1 forms upon LCWE treatment (data not shown).
3.4. Activation of Nlrp3 inﬂammasomes by LCWE is associated with in-
creased lysosome membrane permeability
Next, we investigated the molecular mechanism underlying LCWE-
induced Nlrp3 inﬂammasome activation in MVECs. Previous studies
have demonstrated three pathways to induce Nlrp3 inﬂammasome ac-
tivation inmammalian cells including increased reactive oxygen species
(ROS) production, potassium ion external ﬂow, and lysosomal mem-
brane permeabilization.We ﬁrst examined the effects of N-acetyl-L-cys-
teine, an antioxidant that scavenges oxygen free radicals, and
glibenclamide, a potassium channel blocker, on LCWE-induced
caspase-1 activation and IL-1β production in MVECs. Both N-acetyl-L-
cysteine and glibenclamide had no effects on either LCWE-inducedcaspase-1 activation (Fig. 5A) or IL-1β production (Fig. 5B) in MVECs.
Thus, these results exclude the involvement of potassium ion external
ﬂow or ROS in LCWE-induced activation of Nlrp3 inﬂammasomes.
Previous studies have demonstrated that lysosomal membrane per-
meability is reduced by lysosome stabilization agents such as colchicine,
ceramide, or dexamethasone [25–27]. Colchicine protects suspensions
of lysosomes against spontaneous or induced disruption and has been
termed lysosome “stabilizers” [25]. Ceramide-induced enhancement of
fusion capacity may contribute to the Hsp70-mediated increase in
lysosomal stability [27]. Dexamethasone megadoses may preserve
lysosomal membrane integrity by a dual action involving both rapid
nongenomic effects occurring instantaneously after administration
and long-term receptor-dependent genomic events [26]. In the present
study, we found that these lysosome membrane stabilizing agents
blocked LCWE-induced formation of Nlrp3 inﬂammasomes (Fig. 6A–
B), activation of caspase-1 (Fig. 6C), and production of IL-1β (Fig. 6D)
in MVECs. Taken together, these data suggest that increased lysosome
membrane permeabilization is involved in LCWE-induced Nlrp3
inﬂammasome formation and activation in MVECs.
Fig. 9. Effects of cathepsin B inhibition on LCWE-induced inﬂammasome activity in coronary arterial endothelium ofmice.Mice were intraperitoneally treatedwith saline control (Ctrl) or
LCWE (500 μg, 2 weeks)with orwithout cathepsin B inhibitor Ca-074Me (5mg/kg). (A and B) Frozen sections ofmouse hearts were stainedwith FLICA, a green ﬂuorescent probe speciﬁc
for active caspase-1, and Alexa555-conjugated antibodies against an endothelial cell marker vWF in coronary arteries. Themerged images displayed yellow dots or patches indicating the
colocalization of FLICA (green)with vWF (red). Summarized data showing the colocalization coefﬁcient of FLICAwith vWF. (C and D) IHC staining showing the expression of macrophage
marker F4/80 in the endotheliumof coronary arteries. Summarizeddata showing area percentage of the endotheliumpositive for F4/80 in coronary arteries. (E and F) IHC staining showing
the expression of the neutrophil marker in the endothelium of coronary arteries. Summarized data showing area percentage of the endotheliumpositive for the neutrophilmarker in cor-
onary arteries. Enlarged images of area of interest (AOI) are indicated with an arrow. Scale bar: 50 μm. N = 5 mice per group. *P b 0.05 vs. control; #P b 0.05 vs. LCWE only.
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To directly monitor the changes in lysosome membrane permeabil-
ity in live MVECs, cells were stained with the lysomotropic agent acri-
dine orange which accumulates in acidic organelles such as lysosomes
with red ﬂuorescence and shows green ﬂuorescence in a neutral envi-
ronment such as the cytoplasm and nucleus [28]. Increased lysosome
membrane permeability causes lysosomal alkalization resulting in de-
creased red ﬂuorescence for acridine orange. As shown in Fig. 7A, lyso-
somes in control cells were visualized as red puncta with highﬂuorescent intensity, while LCWE treatment time-dependently de-
creased the number and ﬂuorescence intensity of red puncta. Quantiﬁ-
cation of the red-to-green ﬂuorescence ratio by ﬂow cytometry
(Fig. 7B) further indicated that a maximal decrease by LCWE was ob-
served at 8 h of LCWE stimulation, which was similar to the effect of
glycyl-L-phenylalanine 2-naphthylamide (GPN), a tripeptide causing
osmotic lysis of lysosomes. Lysosomal release of cathepsin B has been
shown to play a crucial role in mediating Nlrp3 inﬂammasome activa-
tion induced by lysosome membrane permeabilization [29,30]. As
shown in Fig. 7C, we also found a marked increase in cathepsin B ex-
pression in the cytosol of MVECs upon LCWE stimulation suggesting
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membrane permeability leading to Nlrp3 inﬂammasome activation.
3.6. Effects of cathepsin B gene silencing on LCWE-induced Nlrp3
inﬂammasome activation in vitro
We further showed that inhibition of cathepsin B activity in MVECs
by silencing cathepsin B genes markedly inhibited LCWE-induced
colocalization of Nlrp3 with caspase-1 (Fig. 8A), cleavage of pro-
caspase-1 (Fig. 8B), and production of IL-1β (Fig. 8C). It was conﬁrmed
that cathepsin B gene silencing by cathepsin B siRNA transfection
could efﬁciently knockdown the cathepsin B protein expression by
78% (Fig. 8D). These ﬁndings further indicate that cathepsin B is in-
volved in LCWE-induced Nlrp3 inﬂammasome activation in MVECs.
3.7. Effects of cathepsin B inhibition on LCWE-inducedNlrp3 inﬂammasome
activation in vivo
A previous study has reported that cathepsin B inhibitor Ca-074Me
could block Nlrp3 inﬂammasome-mediated inﬂammatory responses
in vivo [31]. Similarly, we found that treatment of mice with Ca-
074Me abolished LCWE-induced inﬂammasome activation in coronary
arterial endothelium (Fig. 9A–B). These ﬁndings conﬁrm that cathepsin
B is involved in LCWE-induced endothelial Nlrp3 inﬂammasome activa-
tion in vivo. Furthermore, treatment of mice with Ca-074Me markedly
blocked LCWE-induced increases in the adhesion of inﬂammatory
cells including macrophages (Fig. 9C–D) and neutrophils (Fig. 9E–F).
As shown in Supplementary Fig. S2, Ca-074Me also abolished LCWE-
induced VCAM-1 expression in coronary endothelium. These data sug-
gest that inhibition of cathepsin B also blocks LCWE-induced coronary
arteritis.
4. Discussion
The present study demonstrated that endothelial Nlrp3 inﬂamma-
somes were formed and activated both in vivo and in vitro upon stimu-
lation with LCWE, a bacterial extract that is widely used to induce
coronary arteritis in mice. Such action of LCWE on Nlrp3 inﬂamma-
somes in endothelial cells was associated with increased lysosomal
membrane permeability and cathepsin B release.
Using an establishedmousemodel of Kawasaki disease that involves
injection of LCWE, recent studies have implicated that Nlrp3 inﬂamma-
some is a major intracellular molecular machinery to switch on the in-
ﬂammatory responses that contribute to the development of coronary
arteritis and lesions leading to atherosclerotic acceleration [14,15,32].
It was demonstrated that LCWE-induced IL-1β maturation and secre-
tion was dependent on the Nlrp3 inﬂammasome in macrophages and
both caspase1-deﬁcient and IL-1 receptor-deﬁcient mice were
protected from LCWE-induced coronary lesions [14]. LCWE treatment
of both ApoE−/− and Ldlr−/− mice on the high fat diet, two widely
used geneticmousemodels for atherosclerosis, dramatically accelerated
atherosclerosis in thesemicewith increases in en face aortic atheroscle-
rosis and plaque size in both the aortic sinuses and arch plaques [32].
These previous studies have elegantly demonstrated an essential role
of Nlrp3 inﬂammasome in mediating the inﬂammatory response by
macrophages, however, it remains unknown about the actions of
Nlrp3 inﬂammasomes in vascular cell dysfunction or injury such as
endothelial dysfunction, which has been suggested to be the earliest
step in the development of coronary arteritis as well as atherosclerosis
[33–35]. In the present study, we ﬁrst demonstrated that LCWE-
induced coronary arteritis in a mouse model for Kawasaki disease was
successfully developed as shown by enhanced endothelial expression
of VCAM-1 and increased adhesion of leukocytes to the coronary arterial
walls (Fig. 1). These pathological ﬁndings of LCWE-treated mice also
resembled those of human coronary artery lesions in acute-phase
Kawasaki disease patients, which showed inﬁltration of neutrophils,macrophages and lymphocytes at early stages [36]. Up-regulation of
VCAM-1 has been considered as one of the earlymarkers for endothelial
cell activation anddysfunction,which occurs at the early developmental
stage of various cardiovascular diseases such as atherosclerosis [37–39].
Inhibiting the function of VCAM-1 blocks leukocyte recruitment and
thus tissue inﬂammation in atherosclerosis [37]. More importantly,
our data demonstrated that the changes in VCAM-1 and leukocyte ad-
hesion ability of endothelial cells were correlated with enhanced
Nlrp3 inﬂammasome activity in the coronary endothelium (Fig. 2).
Thus, these ﬁndings support the view that activation of endothelial
Nlrp3 inﬂammasomes may represent an important mechanism that
causes endothelial dysfunction leading to exaggerated inﬂammatory re-
sponses in coronary arteries by the recruitment of inﬂammatory cells
which ultimately contribute to the development of coronary arteritis
and lesions.
By various approaches, we conﬁrmed that LCWE stimulation
induced the formation and activation of the Nlrp3 inﬂammasome
complex in cultured endothelial cells, as shown by colocalization of
Nlrp3 with ASC or caspase-1 using confocal microscopy, by an increase
in the recruitment of pro-caspase-1 to the large molecular fractions
detected by SEC and by biochemical analysis of caspase-1 activity and
production of IL-1β. These results clearly suggest that the Nlrp3
inﬂammasomes are functioning in endothelial cells and that LCWE
stimulation can lead to its activation. Our results are consistent with
previousﬁndings showing that Nlrp3 inﬂammasome,ﬁrst characterized
in immune cells, can also be detected in various non-immune cells
such as endothelial cells and other residential cells in the brain, heart,
and vessels [40]. Although there are some reports that Nlrp3
inﬂammasomes can be activated in endothelial cells under different
pathological conditions such as shear stress, hemorrhagic shock, and
diet-induced dyslipidemia [22,41,42], the results from the present
study provide the ﬁrst experimental evidence that LCWE activates
Nlrp3 inﬂammasomes in endothelial cells, which may be an important
pathogenic mechanism responsible for endothelial dysfunction in the
context of coronary arteritis.
Another important ﬁnding of the present study is that LCWE-
induced Nlrp3 inﬂammasome activation is primarily through a
lysosomal destabilization-mediated signalingpathway. Previous studies
have demonstrated that the activation of Nlrp3 inﬂammasomes
proceeds through at least three mutually non-exclusive mechanisms,
including the K+ efﬂux, generation of reactive oxygen species, and
lysosome membrane permeabilization pathway [9,43,44]. In the pres-
ent study, we demonstrated that LCWE-induced endothelial Nlrp3
inﬂammasome activation was independent of K+ channel activity and
ROS production as shown by the ineffectiveness of potassium channel
blocker glibenclamide or ROS scavenger N-acetyl-L-cysteine on LCWE-
induced caspase-1 activation and IL-1β production. In contrast, LCWE-
induced increases in Nlrp3 inﬂammasome formation and functionality
were markedly attenuated by three mechanistically distinct lysosome
stabilization agents, namely colchicine, dexamethasone, and ceramide.
Although these agents have been claimed as lysosome stabilizers, it
should be noted that none of them is speciﬁc for lysosome stabilization
[25–27]. Nonetheless, our data from these mechanistically distinct
stabilizers implicate that lysosome stability controls the Nlrp3
inﬂammasome activation and functionality in response to LCWE. Inter-
estingly, recent studies have demonstrated that hemorrhagic shock or
shear stress increases NADPH oxidase-derived ROS, which promote
the association of a thioredoxin-interacting protein with the Nlrp3 pro-
tein and subsequently induce inﬂammasome activation in endothelial
cells [22,41]. The discrepancy between these previous ﬁndings and
our results for inﬂammasome activation is unclear. It appears that
Nlrp3 inﬂammasome machinery in endothelial cells can be instigated
via distinct mechanisms depending on the types of stimuli or patholog-
ical conditions.
Lysosome destabilization results in the release of cathepsin B, a lyso-
somal hydrolase that induces Nlrp3 inﬂammasome in a number of
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dye acridine orange, the present study provided the ﬁrst direct evidence
that LCWE disrupted lysosomal integrity and a release of lysosomal
cathepsin B into the cytosol. We also blocked cathepsin B function by
silencing its gene and observed that endothelial cells transfected with ca-
thepsin B siRNA showed much less inﬂammasome formation and func-
tionality. Lastly, treatment of mice with cathepsin B inhibitor Ca-074Me
abolished LCWE-induced endothelial inﬂammasome activation in coro-
nary arteries suggesting that inhibition of cathepsin B also blocks LCWE-
induced Nlrp3 activation in endothelial cells in vivo. Thus, our in vitro
and in vivo data conﬁrm the role of the lysosome destabilization-
cathepsin B signaling pathway in inducing Nlrp3 inﬂammasome in endo-
thelial cells upon LCWE stimulation. The present study did not attempt to
deﬁne the mechanism how LCWE induces the lysosome destabilization-
cathepsin B pathway. LCWE are mainly composed of polysaccharides
and it has been reported that lipopolysaccharides from Escherichia coli
or Porphyromonas gingivalis up-regulate the lysosomal-cathepsin B-
dependent signaling in endothelial cells [48,49]. Thus, the effect of
LCWE on endothelial cells may resemble those of lipopolysaccharides
due to their similarity in chemical structures. Furthermore, inhibition of
cathepsin B blocks LCWE-induced coronary arteritis since treatment of
mice with Ca-074Me markedly blocked LCWE-induced increases in
VCAM-1 expression (Supplementary Fig. S2) and adhesion of inﬂamma-
tory cells including macrophages and neutrophils (Fig. 9C–F). These
data imply that lysosomal-cathepsin B-dependent inﬂammasome activa-
tion could be a therapeutic target for coronary arteritis and consequent
lesions.
Our in vitro and in vivo data suggest that activation of endothelial
inﬂammasome by LCWE is associated with endothelial dysfunction
and increased adhesion ability during LCWE-induced coronary arteritis.
However, our in vivo data did not rule out a role of inﬂammasomes in
other cell types such as macrophages in LCWE-induced arteritis. This
is in line with previous ﬁndings that the pathogenesis of LCWE-
induced coronary arteritis is complex and has also been attributed to
the functions of other inﬂammatory cells such T cells [50] and mono-
cytes [51]. The present study did not attempt to dissect the role of endo-
thelial inﬂammasomes from the ones in other cell types. The
implementation of such a goal would require tissue-speciﬁc knockout
animal models (e.g. endothelial cell-deleted Nlrp3 mouse model) in
the future studies. Nonetheless, our data support the view that endothe-
lial inﬂammasome activation may serve as a contributing mechanism
that initiates or exacerbates the development of coronary arteritis and
lesion.
In summary, the present study demonstrated that in a LCWE-treated
mouse model of coronary arteritis, endothelial dysfunction associated
with an increased adhesion ability is correlated with the formation
and activation of Nlrp3 inﬂammasomes in the coronary endothelium.
Such activation of the endothelial Nlrp3 inﬂammasome by LCWE is
due to lysosome membrane permeabilization and cathepsin B release
and can be suppressed by lysosome stabilization agents. Our results pro-
vide newmechanistic insights into understanding themolecular activa-
tion of the inﬂammasome in endothelial cells and its role in endothelial
dysfunction leading to vascular inﬂammation, which may ultimately
contribute to the development of coronary arteritis and lesion.5. Disclosures
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